KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMY) Invested Capital (2016 - 2025)

Historic Invested Capital for Bristol Myers Squibb (BMY) over the last 17 years, with Q4 2025 value amounting to $63.3 billion.

  • Bristol Myers Squibb's Invested Capital fell 377.7% to $63.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $63.3 billion, marking a year-over-year decrease of 377.7%. This contributed to the annual value of $63.3 billion for FY2025, which is 377.7% down from last year.
  • Bristol Myers Squibb's Invested Capital amounted to $63.3 billion in Q4 2025, which was down 377.7% from $67.3 billion recorded in Q3 2025.
  • In the past 5 years, Bristol Myers Squibb's Invested Capital ranged from a high of $88.7 billion in Q4 2021 and a low of $63.3 billion during Q4 2025
  • In the last 5 years, Bristol Myers Squibb's Invested Capital had a median value of $69.2 billion in 2023 and averaged $73.3 billion.
  • As far as peak fluctuations go, Bristol Myers Squibb's Invested Capital surged by 129.82% in 2023, and later plummeted by 2275.67% in 2024.
  • Bristol Myers Squibb's Invested Capital (Quarter) stood at $88.7 billion in 2021, then fell by 5.2% to $84.1 billion in 2022, then increased by 1.3% to $85.2 billion in 2023, then dropped by 22.76% to $65.8 billion in 2024, then decreased by 3.78% to $63.3 billion in 2025.
  • Its Invested Capital stands at $63.3 billion for Q4 2025, versus $67.3 billion for Q3 2025 and $66.4 billion for Q2 2025.